Skip to content
FIND A HEALTH VALLEY ACTOR

>>venture>> Startup Competition: Diatheris and ZiZAN!A Biobotanica awarded

Venture Startup Competition

Several Swiss Health Valley projects were rewarded during the finale of the >>venture>> Startup Competition on 26 June 2023, at the SwissTech Convention Center.     BioSimo : Grand Prize (ZH) Biosimo has been awarded with CHF 150,000 and a McKinsey & Company business consulting package to keep venturing forward successfully. This Zürich-based chemical engineering…

Read More

Three Health Valley projects received a W. A. de Vigier Award

W. A. de Vigier Award 2023

biped.ai, Gaia Technologies and Limula received a W. A. de Vigier Award, each endowed with CHF 100,000. Over 300 submitted projects were submitted.   biped AG from Epalinges (VD) – Independence for the Visually Impaired 270 million visually impaired people worldwide face challenges in their daily mobility, like avoiding obstacles and finding their way. biped…

Read More

Merck inaugurates its Biotech Development Centre in Corsier-sur-Vevey

Merck Biotech Development Center

German laboratory Merck invested CHF 250 million in Corsier-sur-Vevey (VD). The 15,700 m2 building will combine research and production of biotechnology drugs and employ 250 people.   The pharmaceutical company has invested more than 250 million Swiss francs in this “Biotech Development Centre”. It is dedicated to the development and production of active ingredients for…

Read More

Lonza acquires Dutch biotech company Synaffix

Ibex™ Lonza facilit in Visp Switzerland

The Valais-based pharmaceutical subcontractor will pay an initial €100 million, with subsequent milestone payments of up to a further €60 million.     The deal will strengthen Lonza’s portfolio of antibody-drug conjugates (ADCs) through the integration of Synaffix’s platform. According to a recent estimate relayed by Lonza, the ADC market is set to pass the…

Read More

How the flu virus hacks our cells

Virus Grippe

A UNIGE team has discovered how the influenza A virus hijacks the mechanism for importing iron into cells to invade its host.   Influenza epidemics, caused by influenza A or B viruses, result in acute respiratory infection. They kill half a million people worldwide every year. These viruses can also wreak havoc on animals, as…

Read More

6 life sciences startups in the Top 10 of the W. A. de Vigier Award

De Vigier Award

From a record number of over 300 submitted projects, the jury picked their Top 10. On 20 June 2023, up to five of those young leaders will receive a W. A. de Vigier Award, each endowed with CHF 100,000   biped AG from Epalinges (VD) – Independence for the Visually Impaired 270 million visually impaired…

Read More

BIND: Bioinnovation Day Awards

BIND

On 11 May 2023, 31 early stage life sciences projects were presented to the public at the AGORA (Fondation ISREC) near the CHUV in Lausanne, during the Bioinnovation Day. Three of them received and award.   The BIND is an event was organised the PACTT, the Technology transfer office of University of Lausanne (UNIL) and…

Read More

NewBiologix is betting on the industrialization of gene therapy

New Biologix

With CHF 45 million raised, the start-up NewBiologix, officially launched on 11 May 2023 at the Biopôle in Epalinges, has very high ambitions. Its two founders, Igor Fisch and Nicolas Mermod, want to reproduce the model that they had successfully implemented in Geneva with their previous company, Selexis.     NewBiologix SA emerged from stealth…

Read More

Biotech companies thrive in Switzerland

SBA report

Swiss Biotech Report 2023 shows sector weathers global disruption well and continues to play a leading role driving global healthcare innovation     Record revenues of CHF 6.8 billion (USD 7.5 billion) Fundraising of CHF 1.3 billion (USD 1.5 billion) exceeding pre-COVID 19 levels of 2019. CHF 0.78 billion by public companies, CHF 0.55 billion…

Read More

Impossible Materials raises CHF 3,4 Million

Impossible Materials

Suspected of causing cancer, titanium dioxide, a white colouring agent, has been banned from food in Switzerland and Europe since last year. Impossible Materials, a spin-off from the University of Fribourg, has just raised CHF 3.4 million to develop a cellulose-based alternative.   The round, which was led by Mission Possible Capital, was supported by Big Idea…

Read More